US20070031476A1 - Agent and method for treating cancer comprising strontium, amino acid(s) and mineral agent(s) - Google Patents

Agent and method for treating cancer comprising strontium, amino acid(s) and mineral agent(s) Download PDF

Info

Publication number
US20070031476A1
US20070031476A1 US10/575,752 US57575206A US2007031476A1 US 20070031476 A1 US20070031476 A1 US 20070031476A1 US 57575206 A US57575206 A US 57575206A US 2007031476 A1 US2007031476 A1 US 2007031476A1
Authority
US
United States
Prior art keywords
strontium
pharmaceutical agent
agent according
agent
vanadium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/575,752
Other languages
English (en)
Inventor
Thomas Tallberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Helsingfors Institution for Biommunterapi AB
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Assigned to HELSINGFORS INSTITUTION FOR BIOIMMUNTERAPI AB reassignment HELSINGFORS INSTITUTION FOR BIOIMMUNTERAPI AB ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: TALLBERG, THOMAS
Publication of US20070031476A1 publication Critical patent/US20070031476A1/en
Priority to US12/626,980 priority Critical patent/US8703211B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Definitions

  • the present invention aims at providing such an improved agent and method for treating cancer.
  • the invention resides in the utilization of the beneficial effects of strontium, which have been observed in connection with the present invention.
  • the invention hence relates to a pharmaceutical agent comprising strontium (Sr) in combination with (other) specific dietary supplements, such as amino acids, mineral elements and/or vitamins.
  • strontium is utilized in the form of strontium ions.
  • Said ions can be provided by using strontium in the form of a strontium salt, e.g. strontium chloride or strontium oxide.
  • the invention relates to a pharmaceutical agent comprising strontium, at least one amino acid selected from the group consisting of arginine (Arg), serine (Ser), asparagine (Asp), glycine (Gly), glutamine (Glu), and at least one mineral element selected from the group consisting of chromium (Cr), tin (Sn), vanadium (V) and wolfram (W).
  • a pharmaceutical agent comprising strontium, at least one amino acid selected from the group consisting of arginine (Arg), serine (Ser), asparagine (Asp), glycine (Gly), glutamine (Glu), and at least one mineral element selected from the group consisting of chromium (Cr), tin (Sn), vanadium (V) and wolfram (W).
  • the pharmaceutical agent can be in the form of a food additive or a food ingredient.
  • Dairy products in particular yoghurt, are regarded as preferred.
  • the invention also relates to the use of the pharmaceutical agent including strontium for the manufacture of an agent for treatment or prophylaxis of cancer.
  • the invention relates to a method for treatment or prophylaxis of cancer, said method comprising the administration to an individual in need of such treatment the pharmaceutical agent including strontium in an amount sufficient to achieve the desired effect.
  • the treatment and/or prophylaxis also include delaying or prevention of recurrence of the disease.
  • the cancer form is an adenocarcinoma, such as prostate cancer or renal carcinoma, or melanoma.
  • the etiology and prognostic traits in patients suffering from cancer of the prostate gland was elucidated.
  • the aim was to medically restore, in an active but non-invasive way, the normal metabolic balance and mitochondrial control of oncogen transcription in CaP.
  • the treatment successfully used according to the present invention is based on the administration of strontium (Sr) in combination with amino acid(s) and trace element(s).
  • the results obtained in connection with the present invention clearly show that a daily intake of strontium chloride leads to a significant increase in the serum prolactin (PRL) level.
  • PRL serum prolactin
  • DHEAS serum dihydroepiandrosteron sulphate
  • DHEA serum dihydroepiandrosteron
  • FSH follicle stimulating hormone
  • these supplements include natural amino acids, such as arginine (Arg), serine (Ser), asparagine (Asp), glycine (Gly), glutamine (Glu), and lysine (Lys), mineral salts, such as chromium, tin, vanadium and wolfram, and vitamins, such as A, B, C, D, E, K, folic acid and lycopene, as well as neurogenic lipids.
  • natural amino acids such as arginine (Arg), serine (Ser), asparagine (Asp), glycine (Gly), glutamine (Glu), and lysine (Lys)
  • mineral salts such as chromium, tin, vanadium and wolfram
  • vitamins such as A, B, C, D, E, K, folic acid and lycopene, as well as neurogenic lipids.
  • the supplements are used in amounts sufficient to achieve the desired health promoting effect. As will be readily understood by a physician, the amounts will vary depending on the individual and his health status, as well as other factors such as weight, age, nutrition, stress and environmental factors, etc. Examples of suitable amounts include, but are not limited to, about 2-5 g per day of the specific amino acids mentioned, and 0.5-6, preferably 1-3 mg per day of the trace element salts.
  • the vitamins are used in small, well-established physiological amounts.
  • the dosage of lycopene can, for instance, be about 2 mg per day.
  • Neurogenic lipids can be obtained and administered e.g. in the form of brain, purchased and canned by Neurofood Ltd., Finland.
  • the daily intake can correspond for instance to about 50 g brain.
  • the components of the agent can be administered individually. They can also be administered together, as a combined preparation.
  • the clinically active - combined formulation can also be administered as such or together with a conventional foodstuff.
  • the formulation can be prepared e.g. as pre-packed pulvers. Mixing the formulation, or individual pulverized ingredients, in the patients morning yoghurt, as described below, has been found to be preferred; for the consumer it is easy to enjoy in connection with the morning breakfast or as a snack between meals.
  • a preferred combination according to the invention can comprise the following (calculated as daily intake):
  • the composition of the pharmaceutical agent can vary depending on type of cancer, among other things.
  • the agent should include, in particular, strontium and serine, vanadium being the preferred trace element.
  • arginine is regarded as a preferred component.
  • the main components of the agent are strontium, arginine and vanadium, and for the treatment of melanoma, isoleucin and strontium have been shown to have excellent effects, in combination with one of more of the trace elements Cr, Se, Sn, V and W.
  • Radioactive Strontium 89 has, however, earlier been used to scan bonemetastases. Sr homes into the metastases, although only about 10% of the i.v. dose (up to 80 mg SrCl 2 ) may be radioactive 89 Sr it is sufficient for the localization. However, repeated trials to localize bone-metastases were hampered since the scanning became unreliable. Probably the excess of non-radioactive Sr injected was blocking the cell receptors. Therefore, presently technetium is used for this diagnostic purpose. No harmful therapeutic side effects of the long-lasting use of strontium for diagnostic purposes have been reported. In connection with the present invention, radioactive strontium need not be used.
  • DHEAS dihydroepiandrosteron
  • the ZR cells in the adrenal gland are believed to produce a biological factor inducing a decrease in a previously increased PSA level, which is seen as a sign of inhibition of prostate cancer cell growth.
  • the inventor has found that prolonged therapeutic effect can be achieved by carrying out LHRH treatment intermittently using a short cycle, i.e. repeating the treatment only when the patient's PSA and testosterone levels again begin to raise. This can effectively hinder the development of a hormone refractory state.
  • the ZR cells seem to produce at least two unknown endocrine factors which cause an increase in FSH- and/or PRL-levels. Elevation of these hormone reactions signal a positive prognostic sign, especially coupled with a decreased DHEAS.
  • the stimulation of FSH and PRL appear to form an essential part in the cycle preserving the normal gene transcription of prostate cells, probably also involved in the mitochondrial regulation, which can retract oncogen gen transcription in CaP cells.
  • Androgen ablation therapy does not seem to promote inhibition of crucial enzyme reactions, especially the sulphonation of DHEA to DHEAS.
  • a decreasing level of DHEAS seems to constitute an important part of the biological reactions arresting malignant cell growth in the prostate gland.
  • the 5areductase level was found to decrease in certain patients, but the enzyme does not seem to arrest CaP, and does not seem to be as important a prognostic factor as the depressed sulphonation of DHEA or its isomer.
  • a male patient (P1) suffering from prostate cancer was initially orchiectomized 13 years ago.
  • the PSA value was 360 ⁇ g/L
  • the patient ingested a daily amount of 7 mg of strontium oxide, contained in birch ash that he prepared at home and was taking continuously at a dose of about 8 g per day. His bone-pain subsided in 6 months following the beginning of the treatment, the bone-metastases disappeared after four years, and now in year 2003 the patient is in excellent clinical condition.
  • the serum dihydroepiandrosteron sulphate (DHEAS) level is below the detectable limit of 0.8, the dihydroepiandrosteron (DHEA) value is below 2.0, and his prolactin (PRL) value is normal, about 97 mU/I.
  • the follicle stimulating hormone (FSH) level is increased, about 48 IU/I. This value increases in all castrated patients that react positively on the drastic and provocative decrease in the testosteron level resulting from the surgical operation.
  • the laboratory pattern is presented in Table 2.
  • the example concerns patients with confirmed diagnosis for CaP, based on needle biopsies, and having increased FSH levels.
  • the patients are numbered as patients 6-9 in Table 3.
  • the patients FSH levels varied from 19-70 IU/L, as compared to the normal value 9 IU/L.
  • Their PSA levels were usually 20-30 ⁇ g/ml, however, the disease can be stable for years without any treatment or following only dietary measures.
  • the LH-level may be slightly elevated or depressed without affecting the prognosis. DHEA and DHEAS levels were normal or slightly depressed but as long as the FSH is elevated, the prognosis is fair.

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
US10/575,752 2003-10-17 2004-10-15 Agent and method for treating cancer comprising strontium, amino acid(s) and mineral agent(s) Abandoned US20070031476A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/626,980 US8703211B2 (en) 2003-10-17 2009-11-30 Agent and method for treating cancer comprising strontium, amino acid(s) and mineral agent(s)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03103850A EP1523985B1 (en) 2003-10-17 2003-10-17 Non-radioactive strontium agent for treating cancer
EP03103850.8 2003-10-17
PCT/FI2004/000618 WO2005037295A1 (en) 2003-10-17 2004-10-15 Agent and method for treating cancer comprising strontium, amino acid(s) and mineral agent(s)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/626,980 Division US8703211B2 (en) 2003-10-17 2009-11-30 Agent and method for treating cancer comprising strontium, amino acid(s) and mineral agent(s)

Publications (1)

Publication Number Publication Date
US20070031476A1 true US20070031476A1 (en) 2007-02-08

Family

ID=34354592

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/575,752 Abandoned US20070031476A1 (en) 2003-10-17 2004-10-15 Agent and method for treating cancer comprising strontium, amino acid(s) and mineral agent(s)
US12/626,980 Expired - Fee Related US8703211B2 (en) 2003-10-17 2009-11-30 Agent and method for treating cancer comprising strontium, amino acid(s) and mineral agent(s)

Family Applications After (1)

Application Number Title Priority Date Filing Date
US12/626,980 Expired - Fee Related US8703211B2 (en) 2003-10-17 2009-11-30 Agent and method for treating cancer comprising strontium, amino acid(s) and mineral agent(s)

Country Status (11)

Country Link
US (2) US20070031476A1 (no)
EP (1) EP1523985B1 (no)
CN (1) CN1886143B (no)
AT (1) ATE460168T1 (no)
AU (1) AU2004281559B2 (no)
DE (1) DE60331654D1 (no)
DK (1) DK1523985T3 (no)
ES (1) ES2342461T3 (no)
NO (1) NO20062229L (no)
RU (1) RU2363479C2 (no)
WO (1) WO2005037295A1 (no)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130142736A1 (en) * 2010-08-18 2013-06-06 Colgatge-Palmolive Company Oral care product and methods of use and manufacture thereof

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI122450B (fi) * 2007-12-28 2012-01-31 Neurofood Ab Oy Koostumus steriilin inflammaation hoitoon
FI123756B (fi) * 2010-09-21 2013-10-31 Neurofood Ab Oy Parannettu lisäravinne syövän hoitamiseksi tai ennaltaehkäisemiseksi
EP2530068A1 (en) 2011-05-31 2012-12-05 Lacer, S.A. New strontium salts, synthesis and use thereof in the treatment of osteoporosis
WO2013013003A1 (en) * 2011-07-21 2013-01-24 Emory University Methods for treating inflamatory conditions and states, and cancers by antagonizing nf-kb activation
PT3173382T (pt) * 2014-07-21 2023-03-10 Oxolife Sl Sais de tungsténio (vi) utilizados para tratar infertilidade, para estimular a fertilidade e a reprodução normal num mamífero fêmea não diabético, e para melhorar a eficácia das técnicas de reprodução assistida

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB602029A (en) * 1942-04-17 1948-05-19 Western Condensing Co Improvements in or relating to process of manufacturing a vitamin concentrate
GB602209A (en) * 1945-06-13 1948-05-21 Norton Co Hydraulic table reciprocating mechanism
EP0366869A3 (en) * 1988-10-17 1991-06-12 Lycon Ag Bacteriostatic, bactericidal and antifungal composition and methods of use thereof
CN1082845A (zh) 1992-12-21 1994-03-02 颜怀玮 营养平衡强化型矿泉水及制造方法
CN1053091C (zh) * 1993-03-13 2000-06-07 彭建汉 天然竹汁保健饮料
CN1113720A (zh) * 1994-05-24 1995-12-27 云南智成科技实业公司 保健液及其生产方法
US5650316A (en) * 1994-06-06 1997-07-22 Research Development Foundation Uses of triplex forming oligonucleotides for the treatment of human diseases
EP0737471A3 (fr) * 1995-04-10 2000-12-06 L'oreal Utilisation d'un sel d'une métal alcalino-terreux comme inhibiteur de TNF-alpha dans une composition unique et composition obtenue
FR2740341B1 (fr) * 1995-10-26 1997-12-19 Oreal Utilisation de sel de lanthanide, d'etain, de zinc, de manganese, d'yttrium, de cobalt, de baryum, de strontium dans une composition pour la peau
CN1153053A (zh) * 1995-12-28 1997-07-02 汪贵昌 一种治疗肿瘤的克癌灵中药
US5916143A (en) * 1996-04-30 1999-06-29 Apple; Marc G. Brachytherapy catheter system
WO2000007607A1 (en) * 1998-08-04 2000-02-17 Kosbab, John, V. Nutrient and therapeutic compositions for the treatment of cancer
CA2382262C (en) 1999-08-30 2004-12-07 Ocean Nutrition Canada Ltd. A nutritional supplement for lowering serum triglyceride and cholesterol levels
DE60004710T2 (de) * 1999-12-09 2004-07-08 Biosyntech Canada Inc., Laval Mineral-polymer hybrid-zusammensetzung
US6456680B1 (en) * 2000-03-29 2002-09-24 Tci Incorporated Method of strontium-89 radioisotope production
NO20014746D0 (no) * 2001-09-28 2001-09-28 Clas M Kjoelberg Smertelindrende middel
US20040001835A1 (en) * 2002-03-04 2004-01-01 Medimmune, Inc. Prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130142736A1 (en) * 2010-08-18 2013-06-06 Colgatge-Palmolive Company Oral care product and methods of use and manufacture thereof

Also Published As

Publication number Publication date
RU2006115785A (ru) 2007-11-27
NO20062229L (no) 2006-05-18
EP1523985B1 (en) 2010-03-10
EP1523985A1 (en) 2005-04-20
RU2363479C2 (ru) 2009-08-10
CN1886143B (zh) 2011-04-06
US8703211B2 (en) 2014-04-22
AU2004281559B2 (en) 2010-04-01
ATE460168T1 (de) 2010-03-15
US20100074968A1 (en) 2010-03-25
ES2342461T3 (es) 2010-07-07
DE60331654D1 (de) 2010-04-22
AU2004281559A1 (en) 2005-04-28
DK1523985T3 (da) 2010-05-31
CN1886143A (zh) 2006-12-27
WO2005037295A1 (en) 2005-04-28

Similar Documents

Publication Publication Date Title
US8703211B2 (en) Agent and method for treating cancer comprising strontium, amino acid(s) and mineral agent(s)
TW200812503A (en) Compositions, methods and kits for enhancing weight loss while inhibiting loss of lean body mass
EP0703731B1 (fr) Composition a usage alimentaire et/ou pharmaceutique pauvre en polyamines et applications therapeutiques
EP1718290B1 (en) Composition, comprising l-serine, l-isoleucine, folic acid and trace elements, for treating psoriasis
JP3622985B2 (ja) マグネシウム吸収を高め、アテローム性動脈硬化症を防ぐ方法
CN113645966A (zh) 口服吸收高的t4甲状腺激素溶液的给药方案
EP1021087A1 (en) Serotonin containing formulation for oral administration and method of use
EP2234611B1 (en) Composition for treating sterile inflammation
FI123756B (fi) Parannettu lisäravinne syövän hoitamiseksi tai ennaltaehkäisemiseksi
Cipolla et al. Treating metastatic castration-resistant prostate cancer with novel polyamine-free oral nutritional supplementation: Phase I study
EP0703732B1 (fr) Composition a usage alimentaire et/ou pharmaceutique pauvre en polyamines
US20200023025A1 (en) Nutraceutical compositions for dysmetabolic diseases
WO2014052880A1 (en) Nutritional supplements for eye health and related methods

Legal Events

Date Code Title Description
AS Assignment

Owner name: HELSINGFORS INSTITUTION FOR BIOIMMUNTERAPI AB, FIN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:TALLBERG, THOMAS;REEL/FRAME:018601/0630

Effective date: 20060531

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION